Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study. (October 2022) - Saggu, G.; Stroopinsky, D.; Dudek, A.Z.; Olszanski, A.J.; Juric, D.; Dowlati, A.; Vaishampayan, U.; Assad, H.; Rodón, J.; Gibbs, J.; Green, J.; Du, Z.; et al.